> ## Content Index
> Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CSL Seqirus
- URL: https://www.whiteroseintelligence.com/csl-seqirus/
- Published: 1999-01-02T14:44:00.000Z
- Updated: 2025-05-01T22:34:20.000Z
- Author: Liam Sturgess
- Tags: Profiles, #docs, #organization

**CSL Seqirus**, formerly **Seqirus**, is an Australian multinational vaccine development company. It is a subsidiary of CSL Limited.

## History

Seqirus was an exhibitor and sponsor for the OPTIONS IX for the Control of Influenza conference from August 24-28, 2016, in Chicago, Illinois,[\[1\]](#fn1)[\[2\]](#fn2) and the Canadian Immunization Conference 2016 from December 6-8, 2016, in Ottawa, Ontario.[\[3\]](#fn3)

Seqirus was a sponsor for the Canadian Immunization Conference 2018 from December 4-6, 2018, at the Shaw Centre in Ottawa, Ontario.[\[4\]](#fn4)

Seqirus was a sponsor for the OPTIONS X for the Control of Influenza conference from August 26-September 1, 2019, in Singapore.[\[5\]](#fn5)

### COVID-19

Seqirus was a sponsor for the 2021 AMMI Canada - CACMID Annual Conference,[\[6\]](#fn6) the Canadian Immunization Conference 2021[\[7\]](#fn7) and the 2022 British Columbia Pharmacy Association Annual Conference.[\[8\]](#fn8)

On August 26, 2022, CSL announced that Seqirus was being renamed CSL Seqirus.[\[9\]](#fn9)

CSL Seqirus was an exhibitor and event sponsor at OPTIONS XI for the Control of Influenza from September 26-29, 2022, in Belfast, England.[\[10\]](#fn10)[\[11\]](#fn11)

On May 30, 2024, CSL Seqirus announced that it had been awarded a contract by the [Biomedical Advanced Research and Development Authority](https://www.whiteroseintelligence.com/Biomedical-Advanced-Research-and-Development-Authority) (BARDA) to deliver 4.8 million doses of its H5N1 vaccine for the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program, its fourth such award.[\[12\]](#fn12) On June 11, the company announced a similar award from the [European Commission](https://www.whiteroseintelligence.com/European-Commission) for 665,000 doses for the Health Emergency Preparedness and Response Authority (HERA).[\[13\]](#fn13)

## Organization

Seqirus is a member organization of the [Adult Vaccine Access Coalition](https://www.whiteroseintelligence.com/Adult-Vaccine-Access-Coalition),[\[14\]](#fn14) [Alliance for Biosecurity](https://www.whiteroseintelligence.com/Alliance-for-Biosecurity),[\[15\]](#fn15) [BIOTECanada](https://www.whiteroseintelligence.com/BIOTECanada)[\[16\]](#fn16) the Biotechnology Innovation Organization (BIO)[\[17\]](#fn17) the European Federation of Pharmaceutical Industries and Associations (EFPIA)[\[18\]](#fn18) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),[\[19\]](#fn19) and a partner organization of Global Health Progress[\[20\]](#fn20) and the National Foundation for Infectious Diseases (NFID).[\[21\]](#fn21)

### Personnel

| Name              | Position                                                     | Notes                                                                                           |
| ----------------- | ------------------------------------------------------------ | ----------------------------------------------------------------------------------------------- |
| Kristina Bradford | Senior Project Manager[\[22\]](#fn22)                        | BARDA Industry Day 2018                                                                         |
| Randy Deck        | Senior Director, Pandemic Contracts[\[22:1\]](#fn22)         | BARDA Industry Day 2018                                                                         |
| Phyllis Frosst    | Global Director, Health Policy[\[22:2\]](#fn22)              | BARDA Industry Day 2018                                                                         |
| Marie Mazur       | Vice President, Pandemic Response Solutions[\[22:3\]](#fn22) | BARDA Industry Day 2018                                                                         |
| Melissa Puryear   | Legal Counsel[\[22:4\]](#fn22)                               | BARDA Industry Day 2018                                                                         |
| Martina Scionti   | Senior Manager, Strategic Planning[\[22:5\]](#fn22)          | BARDA Industry Day 2018                                                                         |
| Gillian Talley    | Head of Batch Release[\[22:6\]](#fn22)                       | BARDA Industry Day 2018                                                                         |
| Beverly Taylor    | Head of Global Influenza Scientific Policy[\[23\]](#fn23)    | Multivalent COVID vaccines to help address emergence of variants: CMC and clinical implications |

## Activities

CSL Seqirus has provided funding to:

- [Alliance for Aging Research](https://www.whiteroseintelligence.com/Alliance-for-Aging-Research)[\[24\]](#fn24)
- [Allison McGeer](https://www.whiteroseintelligence.com/Allison-McGeer)[\[25\]](#fn25)
- [Canadian Public Health Association](https://www.whiteroseintelligence.com/Canadian-Public-Health-Association) (CPHA)[\[26\]](#fn26)
- [David Fisman](https://www.whiteroseintelligence.com/David-Fisman)[\[27\]](#fn27)
- Families Fighting Flu[\[28\]](#fn28)
- Foundation for Influenza Epidemiology (FIE)[\[29\]](#fn29)
- Immunisation Coalition[\[30\]](#fn30)
- Immunize Canada[\[31\]](#fn31)
- Kathryn Edwards[\[32\]](#fn32)
- Lung Health Foundation (LHF)[\[33\]](#fn33)
- Manish Sadarangani[\[34\]](#fn34)
- Melissa Andrew[\[35\]](#fn35)
- Nelson Lee[\[36\]](#fn36)
- Robert Belshe[\[37\]](#fn37)
- Sinai Health System[\[38\]](#fn38)
- Task Force for Global Health[\[39\]](#fn39)
- Vaccines4Life[\[40\]](#fn40)
- [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization)[\[41\]](#fn41)

## External links

- [Website (Canada)](https://www.cslseqirus.ca/our-company)
- [Website (United States)](https://www.cslseqirus.us/)

---

1. *OPTIONS IX Supporters.* OPTIONS IX. Retrieved July 7, 2017, from <https://web.archive.org/web/20170707010655/http://2016.isirv.org/options-ix-supporters> [↩︎](#fnref1)
2. *Exhibit Opportunities.* Options IX. Retrieved July 6, 2017, from <https://web.archive.org/web/20170706213219/http://2016.isirv.org/exhibit-opportunities> [↩︎](#fnref2)
3. *Final Program.* (2016, December 6). Canadian Immunization Conference. <https://web.archive.org/web/20220320171400/https://www.cpha.ca/sites/default/files/uploads/conferences/2021/cic16-final-program-en.pdf> [↩︎](#fnref3)
4. *CIC 2018 Final Program.* (2018, November). Canadian Immunization Conference. <https://web.archive.org/web/20220320193739/https://cic-cci.ca/wp-content/uploads/2018/11/CIC-2018-Final-Program.pdf> [↩︎](#fnref4)
5. *Options X Supporters.* ISIRV 2019\. Retrieved October 27, 2022, from <https://web.archive.org/web/20221027005431/https://2019.isirv.org/options-x-supporters> [↩︎](#fnref5)
6. *Sponsorship & Exhibitor Prospectus.* (2021, December). Association of Medical Microbiology and Infectious Diseases Canada. <https://web.archive.org/web/20230430042311/https://ammi.ca/wp-content/uploads/2021/12/2022-Sponsorship-.Exhibitor-ProspectusFINAL.pdf> [↩︎](#fnref6)
7. *CIC 2021 Final Program.* (2021). Canadian Public Health Association. <https://web.archive.org/web/20220422103306/https://www.cpha.ca/sites/default/files/uploads/conferences/2021/cic21-program.pdf> [↩︎](#fnref7)
8. *Our Sponsors and Prizes.* British Columbia Pharmacy Association. Retrieved May 22, 2022, from <http://archive.today/2022.05.23-043337/https://www.bcpharmacy.ca/conference/prizes/2022> [↩︎](#fnref8)
9. Coey, S. K. (2022, August 26). *CSL to unite all business units, including Seqirus, under the CSL umbrella.* Fierce Pharma. <https://web.archive.org/web/20220826150412/https://www.fiercepharma.com/marketing/csl-unite-all-business-unit-including-seqirus-under-one-csl-umbrella> [↩︎](#fnref9)
10. *Meet the Exhibitors.* OPTIONS XI. Retrieved October 26, 2022, from <https://web.archive.org/web/20221026234139/https://www.optionsxi2022.org.uk/exhibition-and-sponsors2/meet-the-exhibitors> [↩︎](#fnref10)
11. *Main Sponsors & Supporters.* OPTIONS XI. Retrieved October 26, 2022, from <https://web.archive.org/web/20221026234119/https://www.optionsxi2022.org.uk/exhibition-and-sponsors2/main-sponsors-and-supporters> [↩︎](#fnref11)
12. Dunleavy, K. (2024, May 30). *CSL Seqirus scores 4th award from US government for bird flu pandemic preparedness.* Fierce Pharma. <https://web.archive.org/web/20240812134158/https://www.fiercepharma.com/pharma/csl-seqirus-scores-4th-award-us-government-bird-flu-pandemic-preparedness> [↩︎](#fnref12)
13. *CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU.* (2024, June 11). CSL. <https://web.archive.org/web/20240804012948/https://newsroom.csl.com/2024-06-11-CSL-Seqirus,-a-Proud-Champion-of-Pandemic-Preparedness,-Signs-an-Agreement-with-the-European-Commission-to-Provide-Pre-Pandemic-Vaccines-to-the-EU> [↩︎](#fnref13)
14. *AVAC Member Organizations.* (2021). Adult Vaccine Access Coalition. <http://archive.today/2022.07.08-060340/https://adultvaccinesnow.org/our-membership/avac-member-organizations/> [↩︎](#fnref14)
15. *Who We Are.* Alliance for Biosecurity. Retrieved June 21, 2022, from <http://archive.today/2022.06.21-000415/https://web.archive.org/web/20200812033301/https://www.allianceforbiosecurity.com/who-we-are> [↩︎](#fnref15)
16. *Member Listings.* BIOTECanada. Retrieved August 6, 2024, from <https://web.archive.org/web/20240806080411/https://www.biotech.ca/about/member-listings/> [↩︎](#fnref16)
17. *BIO Member Directory.* Biotechnology Innovation Organization. Retrieved September 30, 2022, from <https://web.archive.org/web/20220930103715/https://www.bio.org/bio-member-directory> [↩︎](#fnref17)
18. *Membership*. (2022). European Federation of Pharmaceutical Industries and Association. <https://web.archive.org/web/20220701031757/https://www.efpia.eu/about-us/membership/> [↩︎](#fnref18)
19. *Companies*. IFPMA. Retrieved July 1, 2022, from <https://web.archive.org/web/20220701150736/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/> [↩︎](#fnref19)
20. *Explore Our Collaborations.* (2022). Global Health Progress. <https://web.archive.org/web/20220403013206/https://globalhealthprogress.org/explore-our-collaborations/> [↩︎](#fnref20)
21. *NFID Partner Organizations.* (2022, January 6). National Foundation for Infectious Diseases. <https://web.archive.org/web/20220716065253/https://www.nfid.org/partners/> [↩︎](#fnref21)
22. *BARDA Industry Day 2018 Post Conference Participant List.* Biomedical Advanced Research and Development Authority. Retrieved February 27, 2023, from <https://web.archive.org/web/20230227080444/https://www.medicalcountermeasures.gov/BARDA/documents/BID2018%5FParticipantList.pdf> [↩︎](#fnref22) [↩︎](#fnref22:1) [↩︎](#fnref22:2) [↩︎](#fnref22:3) [↩︎](#fnref22:4) [↩︎](#fnref22:5) [↩︎](#fnref22:6)
23. Granerod, J. (2021, April 14). *Workshop Report: COVAX Manufacturing and Clinical Development SWAT Teams Workshop on “Multivalent COVID vaccines to help address emergence of variants: CMC and clinical implications.”* The Global Health Network. <https://web.archive.org/web/20230322033935/https://media.tghn.org/medialibrary/2021/04/COVAX%5FVDM%5FCD%5FSWAT%5FTEAM%5FWorkshop%5F20210414%5FMultivalent%5FVaccines%5FFINAL%5FREPORT.pdf> [↩︎](#fnref23)
24. *How We’re Funded.* (2022). Alliance for Aging Research. <https://web.archive.org/web/20220715161317/https://www.agingresearch.org/about-us/how-were-funded/> [↩︎](#fnref24)
25. Chung, H., Buchan, S. A., Campigotto, A., Campitelli, M. A., Crowcroft, N. S., Dubey, V., Gubbay, J. B., Karnauchow, T., Katz, K., McGeer, A. J., McNally, J. D., Mubareka, S., Murti, M., Richardson, D. C., Rosella, L. C., Schwartz, K. L., Smieja, M., Zahariadis, G., & Kwong, J. C. (2020). Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada. *Clinical Infectious Diseases, 73*(5), e1191–e1199\. <https://doi.org/10.1093/cid/ciaa1862> [↩︎](#fnref25)
26. *Corporate partners.* Canadian Public Health Association. Retrieved April 19, 2024, from <https://web.archive.org/web/20240419085756/https://www.cpha.ca/corporate-partners> [↩︎](#fnref26)
27. *New Modelling Study concludes “Unvaccinated are a danger to the Vaccinated”; but Real-World Data proves COVID Vaccines INCREASE Risk of Infection by 400%.* (2022, April 29). The Exposé. <https://web.archive.org/web/20220511165651/https://expose-news.com/2022/04/29/covid-jabs-increase-risk-infection-400percent/> [↩︎](#fnref27)
28. *Our Partners in Preventing Influenza.* Families Fighting Flu. Retrieved August 1, 2024, from <https://web.archive.org/web/20240801141143/https://www.familiesfightingflu.org/donors-sponsors/> [↩︎](#fnref28)
29. *The Foundation for Influenza Epidemiology.* Global Influenza Hospital Surveillance Network. Retrieved March 28, 2022, from <http://archive.today/2022.03.28-193124/https://www.gihsn.org/about-us/the-foundation-for-influenza-epidemiology> [↩︎](#fnref29)
30. *About Us.* Immunisation Coalition. Retrieved December 5, 2021, from <https://web.archive.org/web/20210303185121/https://www.immunisationcoalition.org.au/about-us/> [↩︎](#fnref30)
31. *Member Organizations.* Immunize Canada. Retrieved July 19, 2024, from <https://web.archive.org/web/20240719141916/https://immunize.ca/member-organizations> [↩︎](#fnref31)
32. Permar, S., Creech, C. B., Edwards, K. M., & Walter, E. B. (2021). Proposals to Accelerate Novel Vaccine Development for Children. *Pediatrics, 149*(1). <https://doi.org/10.1542/peds.2021-054593> [↩︎](#fnref32)
33. *Our Partners.* Lung Health Foundation. Retrieved June 9, 2022, from <http://archive.today/2022.06.09-004346/https://lunghealth.ca/our-partners/> [↩︎](#fnref33)
34. Evans, T., Sadarangani, M., Maguire, J., Zinszer, K., & Kellner, J. (2022). *The importance of pediatric vaccination.* COVID-19 Immunity Task Force. <https://web.archive.org/web/20220424080020/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/03/CITF%5FCanCOVID%5F6%5FPediatric-vaccination%5F2022%5FEN%5FFINAL-2.pdf> [↩︎](#fnref34)
35. Waite, N. M., Pereira, J. A., Houle, S. K. D., Gilca, V., & Andrew, M. K. (2021). COVID-19’s impact on willingness to be vaccinated against influenza and COVID-19 during the 2020/2021 season: results from an online survey of Canadian adults 50 years and older. *Vaccines, 9*(4), 346\. <https://doi.org/10.3390/vaccines9040346> [↩︎](#fnref35)
36. Lee, N. (2018). *ICMJE Form for Disclosure of Potential Conflicts of Interest* (pp. 24–26). New England Journal of Medicine. <https://web.archive.org/web/20220511231133/https://www.nejm.org/doi/suppl/10.1056/NEJMoa1716197/suppl%5Ffile/nejmoa1716197%5Fdisclosures.pdf> [↩︎](#fnref36)
37. *Conflicts of Interest in Pfizer Vaccine Trial.* (2022, April 12). ICAN - Informed Consent Action Network. <http://archive.today/2022.04.12-231318/https://www.icandecide.org/ican%5Fpress/conflicts-of-interest-in-pfizer-vaccine-trial/> [↩︎](#fnref37)
38. Coleman, B. L., Sanderson, R., Haag, M. D. M., & McGovern, I. (2021). Reply to Letter to the Editor by Yin et al. *Influenza and Other Respiratory Viruses, 15*(6), 828–829\. <https://doi.org/10.1111/irv.12895> [↩︎](#fnref38)
39. *Annual Report 2021.* The Task Force for Global Health. Retrieved April 20, 2022, from <https://web.archive.org/web/20220215172458/https://www.taskforce.org/annual-report-2021/#section%5F2> [↩︎](#fnref39)
40. *About Us.* Vaccines4Life. Retrieved July 15, 2022, from <https://web.archive.org/web/20220715204513/https://www.vaccines4life.com/about-us/> [↩︎](#fnref40)
41. *Voluntary contributions by fund and by contributor, 2021.* (2022). World Health Organization. <https://web.archive.org/web/20220516042059/https://apps.who.int/gb/ebwha/pdf%5Ffiles/WHA75/A75%5FINF5-en.pdf> [↩︎](#fnref41)